News Tesaro's Zejula primed for EU approval, battle with AZ EU regulators recommend PARP inhibitor Zejula
News Rubraca outshines rivals in ovarian cancer maintenance thera... Clovis' Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
News Clovis and BMS combine cancer drugs in late-stage trials Clovis and BMS research small molecule and antibody combination.
News Tesaro's niraparib approved in ovarian cancer Company nabs maintenance therapy use, but problems on breast cancer trial.
News AZ's Lynparza impresses with new ovarian cancer data UK firm lays down the gauntlet in the PARP inhibitor battle.
News US pharma tariffs of up to 100% finalised by Trump Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
